Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Research Question: Will treating kidney transplant recipients with maximum MPA dosages (in the form of EC-MPS or Myfortic®) along with judicious CNI exposure (cyclosporine/Neoral®) lead to improved cardiovascular outcomes, as measured by the Framingham Risk Score, 7-year major adverse cardiac events (MACE) score and cardiovascular risk inflammatory biomarker profile? Primary Objectives: 1. To improve the Framingham Risk Score and 7-year MACE score for renal transplant recipients, which estimate risk for cardiovascular disease. 2. To improve the cardiovascular risk inflammatory biomarker profile. Hypothesis: The more consistent drug exposure and lower Cmax noted with monitoring cyclosporine using the 2h levels (C2) combined with full dose Myfortic® will decrease Framingham Risk Score, MACE score, as well as markers of inflammation in kidney transplant recipients because: 1. CNI minimization protocols are widely accepted as a strategy to ameliorate allograft and vascular injury. 2. Chronic allograft injury and vascular disease are known inflammatory conditions. 3. The MPA derivatives possess significant anti-inflammatory properties.